» Articles » PMID: 36436006

Do Antidiabetic Drugs Prevent the Transformation of Trophozoite into Cyst Form?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

This study examines the effects of three different drugs with metformin, acarbose and pioglitazone active ingredients used for antidiabetic purposes on cysts and trophozoites. Cultures of trophozoites and cysts were prepared to test the anti-amoebic activity of metformin, acarbose and pioglitazone. Cultures were then prepared for cyst and trophozoite forms and parasites were exposed to different concentrations (0.750 mg/mL, 0.375 mg/mL, 0.186 mg/mL and 0.093 mg/mL) of metformin, acarbose and pioglitazone. As a result of the study, the reproductive potential suppressive effects and conversion from trophozoite form to cyst form of all three substances on trophozoites and cysts were determined. Parasites were counted at 12, 24 and 48 hours in the cell counter after staining with trypan blue. In comparison of the effects of metformin, acarbose and pioglitazone used in the study on trophozoites and cysts, it was observed that all three substances were statistically effective against cysts and trophozoites at a concentration of 0.750 mg/mL. Furthermore, it was determined that all concentrations of the three active substances included in the study significantly decreased the rate of cyst formation even at the end of the 7th day. In this context, it was determined that all three substances have amebicidal effects, and they significantly inhibit the transformation of trophozoites to cyst form. It is thought that these active substances, which are currently used as anti-diabetic, can be used in combination with other drugs in infections based on our study findings.

Citing Articles

Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for Infection.

Vazquez C, Encalada R, Jimenez-Galicia I, Gomez-Escobedo R, Rivera G, Nogueda-Torres B Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861083 PMC: 11768481. DOI: 10.3390/ph18010021.

References
1.
Marciano-Cabral F, Cabral G . Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev. 2003; 16(2):273-307. PMC: 153146. DOI: 10.1128/CMR.16.2.273-307.2003. View

2.
Dudley R, Jarroll E, Khan N . Carbohydrate analysis of Acanthamoeba castellanii. Exp Parasitol. 2009; 122(4):338-43. DOI: 10.1016/j.exppara.2009.04.009. View

3.
Jensen T, Barnes W, Meyers D . Axenic cultivation of large populations of Acanthamoeba castellanii (JBM). J Parasitol. 1970; 56(5):904-6. View

4.
Oldenburg C, Acharya N, Tu E, Zegans M, Mannis M, Gaynor B . Practice patterns and opinions in the treatment of acanthamoeba keratitis. Cornea. 2011; 30(12):1363-8. PMC: 3219806. DOI: 10.1097/ICO.0b013e31820f7763. View

5.
Anwar A, Khan N, Siddiqui R . Combating Acanthamoeba spp. cysts: what are the options?. Parasit Vectors. 2018; 11(1):26. PMC: 5759203. DOI: 10.1186/s13071-017-2572-z. View